RDGLVivos Inc.

About Vivos Inc. (RDGL)

Vivos Inc. (RDGL) is a Medical Devices company headquartered in Kennewick, WA, United States whose shares trade over-the-counter on the OTCQB tier.

Vivos Inc, developed an yttrium-90 brachytherapy device to combat cancer in humans and animals. Testing at Washington State University, the University of Missouri and our pilot veterinary clinic has verified the safety to the patient, the therapist and the family members. IsoPet is commercially available for animal therapy and can deliver very high doses to solid tumors with a single same day therapy. Pre-clinical testing is in progress to generate key data for an Investigational Devise Exemption to the FDA to begin human clinical trials.

Products and services

The products are IsoPet for animal therapy and RadioGel for future human therapy. They are Yttrium-90 beta emitter brachytherapy devices. The solutions are injected into the tumor and the hydrogel component gels upon reaching body temperature. This locks in the Y-90 phosphate particles to deliver very high local doses.

RDGL key facts

Ticker symbol

RDGL

Market tier

OTCQB

Sector

Healthcare

Industry

Medical Devices

Headquarters

Kennewick, WA, United States

Country of incorporation

US

Employees

1

Estimated market cap

$45.34M (as of Apr 9, 2025)

Shares outstanding

453,412,228

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Vivos Inc. leadership

• Dr. Carlton Cadwell — Secretary
• Dr. Michael K Korenko — CEO
• Michael Pollack — Interim CFO

Explore more: Medical Devices stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with R